Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma

Oncolytic Newcastle disease virus (NDV) might be a promising new therapeutic agent for the treatment of pancreatic cancer. We evaluated recombinant NDVs (rNDVs) expressing interferon (rNDV-hIFNβ-F\(_{\rm{0}}\)) or an IFN antagonistic protein (rNDV-NS1-F\(_{\rm{0}}\)), as well as rNDV with increased...

Full description

Bibliographic Details
Main Authors: Pascal Buijs, Stefan van Nieuwkoop, Vincent Vaes, Ron Fouchier, Casper van Eijck, Bernadette van den Hoogen
Format: Article
Language:English
Published: MDPI AG 2015-06-01
Series:Viruses
Subjects:
Online Access:http://www.mdpi.com/1999-4915/7/6/2756
id doaj-d45d7df8bedc473d938d9a4cf3123e1c
record_format Article
spelling doaj-d45d7df8bedc473d938d9a4cf3123e1c2020-11-24T23:13:40ZengMDPI AGViruses1999-49152015-06-01762980299810.3390/v7062756v7062756Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic AdenocarcinomaPascal Buijs0Stefan van Nieuwkoop1Vincent Vaes2Ron Fouchier3Casper van Eijck4Bernadette van den Hoogen5Department of Surgery, Erasmus MC, University Medical Center Rotterdam, 's-Gravendijkwal 230, 3015 CE Rotterdam, The NetherlandsDepartment of Viroscience, Erasmus MC, University Medical Center Rotterdam, 's-Gravendijkwal 230, 3015 CE Rotterdam, The NetherlandsDepartment of Viroscience, Erasmus MC, University Medical Center Rotterdam, 's-Gravendijkwal 230, 3015 CE Rotterdam, The NetherlandsDepartment of Viroscience, Erasmus MC, University Medical Center Rotterdam, 's-Gravendijkwal 230, 3015 CE Rotterdam, The NetherlandsDepartment of Surgery, Erasmus MC, University Medical Center Rotterdam, 's-Gravendijkwal 230, 3015 CE Rotterdam, The NetherlandsDepartment of Viroscience, Erasmus MC, University Medical Center Rotterdam, 's-Gravendijkwal 230, 3015 CE Rotterdam, The NetherlandsOncolytic Newcastle disease virus (NDV) might be a promising new therapeutic agent for the treatment of pancreatic cancer. We evaluated recombinant NDVs (rNDVs) expressing interferon (rNDV-hIFNβ-F\(_{\rm{0}}\)) or an IFN antagonistic protein (rNDV-NS1-F\(_{\rm{0}}\)), as well as rNDV with increased virulence (rNDV-F\(_{\rm{3aa}}\)) for oncolytic efficacy in human pancreatic adenocarcinoma cells. Expression of additional proteins did not hamper virus replication or cytotoxic effects on itself. However, expression of interferon, but not NS1, resulted in loss of multicycle replication. Conversely, increasing the virulence (rNDV-F\(_{\rm{3aa}}\)) resulted in enhanced replication of the virus. Type I interferon was produced in high amounts by all tumor cells inoculated with rNDV-hIFNβ -F\(_{\rm{0}}\), while inoculation with rNDV-NS1-F\(_{\rm{0}}\) resulted in a complete block of interferon production in most cells. Inoculation of human pancreatic adenocarcinoma cells with rNDV-F\(_{\rm{3aa}}\) caused markedly more cytotoxicity compared to rNDV-F\(_{\rm{0}}\), while inoculation with rNDV-hIFNβ -F\(_{\rm{0}}\) and rNDV-NS1-F\(_{\rm{0}}\) induced cytotoxic effects comparable to those induced by the parental rNDV-F\(_{\rm{0}}\). Evaluation \textit{in vivo} using mice bearing subcutaneous pancreatic cancer xenografts revealed that only intratumoral injection with rNDV-F\(_{\rm{3aa}}\) resulted in regression of tumors. We conclude that although lentogenic rNDVs harboring proteins that modulate the type I interferon pathway proteins do have an oncolytic effect, a more virulent mesogenic rNDV might be needed to improve oncolytic efficacy.http://www.mdpi.com/1999-4915/7/6/2756oncolytic virusoncolytic virotherapyNewcastle disease viruspancreatic adenocarcinomainnate immunityimmunotherapy
collection DOAJ
language English
format Article
sources DOAJ
author Pascal Buijs
Stefan van Nieuwkoop
Vincent Vaes
Ron Fouchier
Casper van Eijck
Bernadette van den Hoogen
spellingShingle Pascal Buijs
Stefan van Nieuwkoop
Vincent Vaes
Ron Fouchier
Casper van Eijck
Bernadette van den Hoogen
Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma
Viruses
oncolytic virus
oncolytic virotherapy
Newcastle disease virus
pancreatic adenocarcinoma
innate immunity
immunotherapy
author_facet Pascal Buijs
Stefan van Nieuwkoop
Vincent Vaes
Ron Fouchier
Casper van Eijck
Bernadette van den Hoogen
author_sort Pascal Buijs
title Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma
title_short Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma
title_full Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma
title_fullStr Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma
title_full_unstemmed Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma
title_sort recombinant immunomodulating lentogenic or mesogenic oncolytic newcastle disease virus for treatment of pancreatic adenocarcinoma
publisher MDPI AG
series Viruses
issn 1999-4915
publishDate 2015-06-01
description Oncolytic Newcastle disease virus (NDV) might be a promising new therapeutic agent for the treatment of pancreatic cancer. We evaluated recombinant NDVs (rNDVs) expressing interferon (rNDV-hIFNβ-F\(_{\rm{0}}\)) or an IFN antagonistic protein (rNDV-NS1-F\(_{\rm{0}}\)), as well as rNDV with increased virulence (rNDV-F\(_{\rm{3aa}}\)) for oncolytic efficacy in human pancreatic adenocarcinoma cells. Expression of additional proteins did not hamper virus replication or cytotoxic effects on itself. However, expression of interferon, but not NS1, resulted in loss of multicycle replication. Conversely, increasing the virulence (rNDV-F\(_{\rm{3aa}}\)) resulted in enhanced replication of the virus. Type I interferon was produced in high amounts by all tumor cells inoculated with rNDV-hIFNβ -F\(_{\rm{0}}\), while inoculation with rNDV-NS1-F\(_{\rm{0}}\) resulted in a complete block of interferon production in most cells. Inoculation of human pancreatic adenocarcinoma cells with rNDV-F\(_{\rm{3aa}}\) caused markedly more cytotoxicity compared to rNDV-F\(_{\rm{0}}\), while inoculation with rNDV-hIFNβ -F\(_{\rm{0}}\) and rNDV-NS1-F\(_{\rm{0}}\) induced cytotoxic effects comparable to those induced by the parental rNDV-F\(_{\rm{0}}\). Evaluation \textit{in vivo} using mice bearing subcutaneous pancreatic cancer xenografts revealed that only intratumoral injection with rNDV-F\(_{\rm{3aa}}\) resulted in regression of tumors. We conclude that although lentogenic rNDVs harboring proteins that modulate the type I interferon pathway proteins do have an oncolytic effect, a more virulent mesogenic rNDV might be needed to improve oncolytic efficacy.
topic oncolytic virus
oncolytic virotherapy
Newcastle disease virus
pancreatic adenocarcinoma
innate immunity
immunotherapy
url http://www.mdpi.com/1999-4915/7/6/2756
work_keys_str_mv AT pascalbuijs recombinantimmunomodulatinglentogenicormesogeniconcolyticnewcastlediseasevirusfortreatmentofpancreaticadenocarcinoma
AT stefanvannieuwkoop recombinantimmunomodulatinglentogenicormesogeniconcolyticnewcastlediseasevirusfortreatmentofpancreaticadenocarcinoma
AT vincentvaes recombinantimmunomodulatinglentogenicormesogeniconcolyticnewcastlediseasevirusfortreatmentofpancreaticadenocarcinoma
AT ronfouchier recombinantimmunomodulatinglentogenicormesogeniconcolyticnewcastlediseasevirusfortreatmentofpancreaticadenocarcinoma
AT caspervaneijck recombinantimmunomodulatinglentogenicormesogeniconcolyticnewcastlediseasevirusfortreatmentofpancreaticadenocarcinoma
AT bernadettevandenhoogen recombinantimmunomodulatinglentogenicormesogeniconcolyticnewcastlediseasevirusfortreatmentofpancreaticadenocarcinoma
_version_ 1725597264077914112